- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Envida® | KN-035 | KN035
envafolimab is an approved drug (China (2021))
Compound class: Antibody
Comment: Envafolimab (KN035) is a chimeric (human/camelid) anti-PD-L1 nanobody that acts as an immune checkpoint inhibitor, and which is being developed by Alphamab Co . Structurally it is a VH-Fc dimer, and does not contain variable light (VL) domains. It therefore has a reduced molecular size and offers more favourable physico-chemical properties than full-size monoclonal antibodies. X-ray crystal structures show that KN035 binds to the same surface on PD-L1 where the ligand interacts with its cognate receptor PD-1 (programmed death protein 1).
The peptide sequence of envafolimab's heavy chain returned no matches with patented peptide sequences in a Protein: BLAST search in September 2019.
|Approved drug?||Yes (China (2021))|
|International Nonproprietary Names|
|Envida® | KN-035 | KN035|
|GtoPdb PubChem SID||387065574|
|Search PubMed clinical trials||envafolimab|
|Search PubMed titles||envafolimab|
|Search PubMed titles/abstracts||envafolimab|